Inspire Medical Systems, Inc. (INSP) Securities Class Action Lawsuit Filed [November 11, 2025]

Introduction to Inspire Medical Systems, Inc. (INSP) Securities Class Action Lawsuit

A federal securities fraud class action has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) covering purchases from August 6, 2024 through August 4, 2025. Investors allege the company and senior executives misrepresented the readiness, demand, and success of the launch of its "next generation" sleep apnea device, Inspire V. According to the complaint, management repeatedly assured the market that regulatory, technical, and commercial conditions were satisfied and that payer policies and reimbursement were in place. On August 4, 2025, Inspire disclosed an "elongated timeframe" for the launch, admitting widespread gaps in training and onboarding, delayed claims software updates for Medicare billing until July 1, and poor demand amid excess inventory. The next day, the stock fell more than 32%—a $42.04 drop to $87.91—wiping out $1.2 billion in market value.

Inspire Medical Systems, Inc. (INSP) Securities Lawsuit Case Details

Case Name: City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al.
Case No.: 0:25-cv-04247
Jurisdiction: U.S. District Court, District of Minnesota
Filed on: November 6, 2025

Inspire Medical Systems, Inc. (INSP) Company Profile

Inspire Medical Systems, Inc. is a Delaware medical technology company that develops and manufactures an implantable device for obstructive sleep apnea. Its latest iteration, Inspire V, uses an implanted sensor and neurostimulator designed to improve respiration during sleep.

Inspire Medical Systems, Inc. (INSP) Securities Lawsuit Class Period

August 6, 2024–August 4, 2025, inclusive.

All persons and entities that purchased or otherwise acquired the publicly traded common stock of Inspire during the Class Period are within the alleged class and may be eligible to join the Inspire Medical Systems, Inc. (INSP) class action lawsuit.

Allegations in the Inspire Medical Systems, Inc. (INSP) Securities Class Action Lawsuit

The complaint tags Inspire Medical Systems, Inc. and three executives: Timothy Herbert, the President, Chief Executive Officer, and Chairman; Richard Buchholz, the Chief Financial Officer; and Carlton Weatherby, the Chief Strategy and Growth Officer. Investors allege these defendants told the market throughout the period that Inspire V's launch conditions were met, demand was strong, and the rollout was proceeding successfully.

The story begins on August 6, 2024, when CEO Herbert said the company was shifting to "operational readiness" and building inventory to support a soft launch in late 2024 and a full launch in 2025, emphasizing the need for "continuous supply." On September 4, 2024, CFO Buchholz told investors that the market's 2025 revenue consensus was "reasonable" in part because Inspire V "will help in 2025," while Weatherby said the soft launch would capture real-time feedback to "hit the ground running" at full launch.

As the calendar turned, management kept that message. On January 13, 2025, Herbert reported the soft launch had started in Singapore with "tremendous" feedback, said the company was building inventory for full launch, and claimed Inspire was "at the cusp" of launching Inspire V. On February 10, 2025, he stated the SleepSync programming system was fully launched in the U.S., described continued experience with the soft launch while moving toward full launch that year, and said the main gating factor was building enough inventory to meet expected demand while working with "every payer" to update policies. By May 5, 2025, Inspire announced it was beginning the full launch, touting very positive provider reception, asserting the CPT code had been incorporated into policies covering approximately 80% of over 300 million covered lives across commercial payers, Medicare, and the VA, and declaring the company "ready to throw the switch" with expectations for a strong second half of 2025.

According to the complaint, the reality behind the scenes was starkly different. The Inspire V launch allegedly faltered because demand was poor as providers held surplus inventory and resisted switching treatments. Plaintiffs allege Inspire had not completed essential launch tasks: "many" treatment centers lacked training and onboarding; basic IT systems, including a customer approval process, were not set; critical insurer claims software was not properly updated; and Medicare reimbursement was not in place at launch.

The Truth Emerges

The curtain lifted on August 4, 2025. Inspire announced the Inspire V rollout faced an "elongated timeframe" due to undisclosed headwinds, acknowledging that many centers had not completed the training, contracting, and onboarding required before purchasing and implanting Inspire V. Management further admitted that, while the CPT code existed for Medicare, the necessary software updates for claims submission and processing did not take effect until July 1, meaning centers could not bill for those procedures until that date and many continued using Inspire IV. Investors also learned the rollout was hampered by poor demand linked to excess inventory.

These admissions cut against the company's prior assurances of launch readiness, strong demand, and payer preparedness. Representations about inventory sufficiency, policy updates with "every payer," and smooth progression from soft to full launch were contradicted by the late-arriving billing software, incomplete customer onboarding, and the market's reluctance to transition.

Market Reaction

The market reacted the next day. On August 5, 2025, Inspire's stock fell more than 32%, or by $42.04 per share to close at $87.91, eliminating approximately $1.2 billion in market capitalization in a single trading day.

The decline compounded a larger slide from the class-period closing high of $216.71 on September 23, 2024 to August 5, 2025, when the stock fell $127.00 per share, or nearly 60%, erasing billions of dollars in value. 

Next Steps

• Submissions for lead plaintiff are due January 5, 2026.
• The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
• The Court will then consider motion for class certification.
• The Court will later consider a Motion to Dismiss.

To learn if you are eligible for recovery under the INSP securities class action lawsuit, visit the case submission page here.

 Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.